The Prospect of Repurposing Immunomodulatory Drugs for Adjunctive Chemotherapy against Tuberculosis: A Critical Review
Tuberculosis (TB) remains a global health emergency, with an estimated 2 billion people infected across the world, and 1.4 million people dying to this disease every year. Many aspects of the causative agent, <i>Mycobacterium tuberculosis</i>, make this disease difficult for healthcare a...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-01-01
|
| Series: | Antibiotics |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2079-6382/10/1/91 |
| _version_ | 1827599866969194496 |
|---|---|
| author | Chiyun Lee Sanjib Bhakta |
| author_facet | Chiyun Lee Sanjib Bhakta |
| author_sort | Chiyun Lee |
| collection | DOAJ |
| description | Tuberculosis (TB) remains a global health emergency, with an estimated 2 billion people infected across the world, and 1.4 million people dying to this disease every year. Many aspects of the causative agent, <i>Mycobacterium tuberculosis</i>, make this disease difficult for healthcare and laboratory researchers to fight against, such as unique pathophysiology, latent infection and long and complex treatment regimens, thus causing patient non-compliance with the treatment. Development of new drugs is critical for tackling these problems. Repurposing drugs is a promising strategy for generating an effective drug treatment whilst circumventing many of the challenges of conventional drug development. In this regard, the incorporation of immunomodulatory drugs into the standard regimen to potentiate frontline drugs is found to be highly appealing. Drugs of diverse chemical classes and drug categories are increasingly being evidenced to possess antitubercular activity, both in vitro and in vivo. This article explores and discusses the molecular entities that have shown promise in being repurposed for use in anti-TB adjunctive therapy and aims to provide the most up-to-date picture of their progress. |
| first_indexed | 2024-03-09T04:23:25Z |
| format | Article |
| id | doaj.art-edc87ef1e7484dc99a1616dc66f3cb83 |
| institution | Directory Open Access Journal |
| issn | 2079-6382 |
| language | English |
| last_indexed | 2024-03-09T04:23:25Z |
| publishDate | 2021-01-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Antibiotics |
| spelling | doaj.art-edc87ef1e7484dc99a1616dc66f3cb832023-12-03T13:44:33ZengMDPI AGAntibiotics2079-63822021-01-011019110.3390/antibiotics10010091The Prospect of Repurposing Immunomodulatory Drugs for Adjunctive Chemotherapy against Tuberculosis: A Critical ReviewChiyun Lee0Sanjib Bhakta1Department of Biochemistry, University of Cambridge, Hopkins Building, Tennis Court Road, Cambridge CB2 1QW, UKMycobacteria Research Laboratory, Department of Biological Sciences, The Institute of Structural and Molecular Biology, Birkbeck, University of London, Malet Street, London WC1E 7HX, UKTuberculosis (TB) remains a global health emergency, with an estimated 2 billion people infected across the world, and 1.4 million people dying to this disease every year. Many aspects of the causative agent, <i>Mycobacterium tuberculosis</i>, make this disease difficult for healthcare and laboratory researchers to fight against, such as unique pathophysiology, latent infection and long and complex treatment regimens, thus causing patient non-compliance with the treatment. Development of new drugs is critical for tackling these problems. Repurposing drugs is a promising strategy for generating an effective drug treatment whilst circumventing many of the challenges of conventional drug development. In this regard, the incorporation of immunomodulatory drugs into the standard regimen to potentiate frontline drugs is found to be highly appealing. Drugs of diverse chemical classes and drug categories are increasingly being evidenced to possess antitubercular activity, both in vitro and in vivo. This article explores and discusses the molecular entities that have shown promise in being repurposed for use in anti-TB adjunctive therapy and aims to provide the most up-to-date picture of their progress.https://www.mdpi.com/2079-6382/10/1/91tuberculosisdrug resistancerepurposingimmunomodulatory drugsNSAIDsadjunctive therapy |
| spellingShingle | Chiyun Lee Sanjib Bhakta The Prospect of Repurposing Immunomodulatory Drugs for Adjunctive Chemotherapy against Tuberculosis: A Critical Review Antibiotics tuberculosis drug resistance repurposing immunomodulatory drugs NSAIDs adjunctive therapy |
| title | The Prospect of Repurposing Immunomodulatory Drugs for Adjunctive Chemotherapy against Tuberculosis: A Critical Review |
| title_full | The Prospect of Repurposing Immunomodulatory Drugs for Adjunctive Chemotherapy against Tuberculosis: A Critical Review |
| title_fullStr | The Prospect of Repurposing Immunomodulatory Drugs for Adjunctive Chemotherapy against Tuberculosis: A Critical Review |
| title_full_unstemmed | The Prospect of Repurposing Immunomodulatory Drugs for Adjunctive Chemotherapy against Tuberculosis: A Critical Review |
| title_short | The Prospect of Repurposing Immunomodulatory Drugs for Adjunctive Chemotherapy against Tuberculosis: A Critical Review |
| title_sort | prospect of repurposing immunomodulatory drugs for adjunctive chemotherapy against tuberculosis a critical review |
| topic | tuberculosis drug resistance repurposing immunomodulatory drugs NSAIDs adjunctive therapy |
| url | https://www.mdpi.com/2079-6382/10/1/91 |
| work_keys_str_mv | AT chiyunlee theprospectofrepurposingimmunomodulatorydrugsforadjunctivechemotherapyagainsttuberculosisacriticalreview AT sanjibbhakta theprospectofrepurposingimmunomodulatorydrugsforadjunctivechemotherapyagainsttuberculosisacriticalreview AT chiyunlee prospectofrepurposingimmunomodulatorydrugsforadjunctivechemotherapyagainsttuberculosisacriticalreview AT sanjibbhakta prospectofrepurposingimmunomodulatorydrugsforadjunctivechemotherapyagainsttuberculosisacriticalreview |